Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Liu, Kai-Yan  [Clear All Filters]
2016
Tang, F.-F., Huang, X.-J., Zhang, X.-H., Chen, H., Chen, Y.-H., Han, W., Chen, Y., Wang, F.-R., Wang, Y., Wang, J.-Z., et al. (2016). Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.Leuk Res47, 8-15.
Xu, L.-P., Xu, Z.-L., Zhang, X.-H., Chen, H., Chen, Y.-H., Han, W., Chen, Y., Wang, F.-R., Wang, J.-Z., Wang, Y., et al. (2016). Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.Biol Blood Marrow Transplant.
Shi, M.-M., Kong, Y., Song, Y., Sun, Y.-Q., Wang, Y., Zhang, X.-H., Xu, L.-P., Liu, K.-Y., and Huang, X.-J. (2016). Atorvastatin enhances endothelial cell function in post transplant poor graft function.Blood.
Zhang, X.-H., Feng, F.-E., Han, W., Wang, F.-R., Wang, J.-Z., Wang, Y., Chen, Y., Fu, H.-X., Mo, X.-D., Zhang, Y.-Y., et al. (2016). High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation.Thromb Res144, 6-11.
Kong, Y., Song, Y., Hu, Y., Shi, M.-M., Wang, Y.-T., Wang, Y., Zhang, X.-H., Xu, L.-P., Liu, K.-Y., Deng, H.-K., et al. (2016). Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants.Oncotarget.
Tian, D.-M., Wang, Y., Zhang, X.-H., Liu, K.-Y., Huang, X.-J., and Chang, Y.-J. (2016). Rapid Recovery of CD3+CD8+ T Cells on Day 90 Predicts Superior Survival after Unmanipulated Haploidentical Blood and Marrow Transplantation.Plos One11, e0156777.
Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., et al. (2016). Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy.Biol Blood Marrow Transplant.
2018
Xue, Y.-J., Cheng, Y.-F., Lu, A.-D., Wang, Y., Zuo, Y.-X., Yan, C.-H., Wu, J., Sun, Y.-Q., Suo, P., Chen, Y.-H., et al. (2018). Allogeneic hematopoietic stem cell transplantation, especially haploidentical HSCT, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.Biol Blood Marrow Transplant.
Chang, Y.-J., Xu, L.-P., Wang, Y., Zhang, X.-H., Chen, H., Chen, Y.-H., Wang, F.-R., Han, W., Sun, Y.-Q., Yan, C.-H., et al. (2018). Effects of low-dose glucocorticoid prophylaxis on chronic GVHD and GVHD-free, relapse-free survival after haploidentical transplantation: long-term follow-up of a controlled, randomized open-label trial.Biol Blood Marrow Transplant.
Yan, C.-H., Wang, Y., Mo, X.-D., Sun, Y.-Q., Wang, F.-R., Fu, H.-X., Chen, Y., Han, T.-T., Kong, J., Cheng, Y.-F., et al. (2018). Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation.Clin Infect Dis67, S162-S173.
Huo, M.-R., Xu, Y.-J., Zhai, S.-Z., Lv, M., Wang, Y., Cao, L.-Q., Xu, L.-P., Zhang, X.-H., Chen, H., Chen, Y.-H., et al. (2018). Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study.Hum Immunol.
2019
Ma, R., Huang, X.-J., Xu, L.-P., Liu, K.-Y., Zhang, X.-H., Yan, C.-H., Han, W., Wang, F.-R., Chen, Y.-H., Chen, H., et al. (2019). Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies.Biol Blood Marrow Transplant.
Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., et al. (2019). Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 19.Biol Blood Marrow Transplant.
Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., et al. (2019). Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (.Biol Blood Marrow Transplant.
Zhao, X.-Y., Pei, X.-Y., Chang, Y.-J., Yu, X.-X., Xu, L.-P., Wang, Y., Zhang, X.-H., Liu, K.-Y., and Huang, X.-J. (2019). First-line therapy with donor-derived HCMV-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation.Clin Infect Dis.
Zhang, Y.-Y., Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., et al. (2019). FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.Bone Marrow Transplant.
Wang, X.-Y., Fan, Q.-Z., Xu, L.-P., Wang, Y., Zhang, X.-H., Chen, H., Chen, Y.-H., Wang, F.-R., Han, W., Sun, Y.-Q., et al. (2019). The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.Cytometry B Clin Cytom.
Qin, Y.-Z., Wang, Y., Xu, L.-P., Zhang, X.-H., Zhao, X.-S., Liu, K.-Y., and Huang, X.-J. (2019). Subgroup Analysis Can Optimize the Relapse Prediction Cutoff Value for WT1 Expression Following Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia.J Mol Diagn.
Xue, Y.-J., Suo, P., Huang, X.-J., Lu, A.-D., Wang, Y., Zuo, Y.-X., Yan, C.-H., Wu, J., Kong, J., Zhang, X.-H., et al. (2019). Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukae.Br J Haematol.